3/22/04

10/805,885

INFORMATION DISCLOSURE CITATION *(Use several sheets if necessary)*	ATTY. DOCKET NO. PC25078A	SERIAL NO. ~~To be assigned~~
	APPLICANT John W. Benbow, et al.	
	FILING DATE Concurrently herewith	GROUP 1624 ~~To be assigned~~

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	~~US~~	~~0~~	~~1~~	~~0~~	~~3~~	~~1~~	~~8~~	~~5~~	~~08/01/02~~	~~Sanner et al.~~	~~A61K~~	~~31/55~~	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

ZT			Singh, P. et al., Indian Journal of Chemistry, Vol. 35B, pp. 929-934, September 1996, "Fujita-Ban and Hansch analyses of A_1- and A_2-adenosine receptor binding affinities of some 4-amino[1,2,4]triazolo[4,3-α]quinoxalines."
ZT			Sarges, R. et al., J. Med. Chem., Vol. 33, pp. 2240-2254, 1990, "4-Amino[1,2,4]triazolo[4,3-α]quinoxalines. A Novel Class of Potent Adenosine Receptor Antagonists and Potential Rapid-Onset Antidepressants."
ZT			Adenot, M. et al., Eur J Med Chem, Vol. 32, pp. 493-504, 1997, "Interest of cluster significance analysis in structure-affinity relationships for non-xanthine heterocyclic antagonists of adenosine."
ZT			Colotta, V. et al., Arch. Pharm. Pharm. Med. Chem., Vol. 332, pp. 39-41, ~~4991~~ (1999), "4-Amino-6-benzylamino-1,2-dihydro-2-phenyl-1,2,4-triazolo[4,3-α]-quinoxalin-1-one: A New A_{2A} Adenosine Receptor Antagonist with High Selectivity *versus* A1 Receptors."
ZT			Colotta, V. et al., J. Med. Chem., Vol. 43, pp. 1158-1164, 2000, "1,2,4-Triazolo[4,3-α]quinoxalin-1-one: A Versatile Tool for the Synthesis of Potent and Selective Adenosine Receptor Antagonists."

EXAMINER Zachary Tidwell DATE CONSIDERED 21 FEBRUARY 2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION *(Use several sheets if necessary)*	ATTY. DOCKET NO. PC25078A	SERIAL NO. 10/805,885
	APPLICANT John W. Benbow et al.	
	FILING DATE 03/22/04	GROUP ~~1614~~ 1624

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	~~US~~	~~02 1 6 5 1 0 7~~	~~11.07.02~~	~~Fishman et al~~	~~514~~	~~46~~	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
ZT	EP 1 0 5 0 5 3 5		08.11.00	EP	C07D	487/04		
ZT	WO 02 0 8 3 1 4 0		24.10.02	International	A61K	31/5025		
ZT	EP 1 2 9 5 8 8 5		26.03.03	EP	C07D	487/04		
ZT	WO 0 2 5 0 0 7 9		27.06.02	International	C07D	487/04		

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

ZT			Smith, David et al., 3-Anilino-4-arylmaleimides: Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 (GSK-3), Pergamon Bioorganic & Medicinal Chemistry Letters 11 (2001) pp. 635-639.
ZT			Bertrand, J.A., et al., Structural Characterization of the GSK-3B Active Site Using Selective and Non-selective ATP-mimetic Inhibitors, J.Mol.Biol. (2003) 333, 393-407.

EXAMINER [signature] DATE CONSIDERED 21 FEBRUARY 2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.